Coya Therapeutics, Inc. recently announced the issuance of a U.S. patent for its investigational ready-to-use liquid formulation of IL-2. The patent, numbered US 12,312,389 B2, covers methods of producing highly stable liquid formulations of IL-2, also known as aldesleukin. This development marks a significant milestone for Coya, as the patent is part of a broader intellectual property portfolio that includes combinations with other biologics, such as CTLA-4 Ig and GLP-1 agonists. The company plans to continue expanding its IP portfolio and is on track to submit an IND for a combination therapy involving low-dose rhIL-2 and CTLA4-Ig by the end of June, aimed at initiating a Phase 2b study in ALS patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.